1. Considered and approved the standalone audited financial results of the company for the quarter and financial year ended 31st March 2025. 2. Appointment of Mr. Yogainder Kumar Gupta ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Genomic Valley Biotech's board, meeting on 30th May 2025, approved audited standalone financial results for Q4 and FY ended 31st March 2025, with the statutory auditor issuing an unmodified (clean) opinion. For the full year, revenue from operations jumped to about Rs. 84.39 lakh from Rs. 16.51 lakh last year, and net profit surged to Rs. 35.61 lakh from Rs. 1.52 lakh, lifting EPS to Rs. 1.17 from Rs. 0.05. The board also appointed Mr. Yogainder Kumar Gupta (former finance and real estate professional, 44 years' experience) as an Additional Non-Executive Independent Director for a five-year term starting 30th May 2025, subject to shareholder approval. Additionally, M/s SBR & Co. LLP was appointed as Secretarial Auditor for FY24-25, and the Audit, Stakeholders' Relationship, Nomination & Remuneration, and Risk Management committees were reconstituted.
Strong turnaround in FY25 financials with revenue and profit multiples higher than last year, along with a clean audit report, is a positive signal for shareholders. Adding a new independent director and a secretarial auditor strengthens board oversight, though these are largely routine governance steps rather than stock-moving events.